Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Neumora Therapeutics, Inc. (NMRA)

Neumora reports favorable NMRA-215 toxicology results, plans IND in Q4 2026

Positive Impact 3 of 5 other Written later

Neumora Therapeutics said a repeat 13-week rat toxicology study of NMRA-215 showed no unexpected in-life adverse findings, after an earlier study had reported such findings in 5 of 142 animals. The company continues to believe the earlier findings were not related to NMRA-215 and plans to submit an IND application in the fourth quarter of 2026.

Key points

  • Repeat 13-week rat toxicology study in 162 animals showed no unexpected in-life adverse findings.
  • A for-cause audit of the earlier study found various discrepancies and a number of critical audit observations.
  • The company plans to submit an IND in the fourth quarter of 2026 and initiate a Phase 1 study by the end of 2026.

The filing

CompanyNeumora Therapeutics, Inc. (NMRA)
Form8-K, current report
Filed with the SECJul 27, 2026, 7:07 AM ET
Accession number0001193125-26-316819

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 27, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.